ReviewPediatric radiology2026
Differentiating focal nodular hyperplasia from hepatic adenoma using a multimodality approach in children.
Review in Pediatric radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiological characterisation of liver tumours in children aims to differentiate benign from malignant or potentially malignant lesions, and where possible, obviate the need for biopsy. This approach aims to reduce unnecessary morbidity and parental/patient anxiety and promotes judicious use of radiological and surgical resources. Focal nodular hyperplasia (FNH) and hepatic adenoma usually have a benign course but require tailored imaging follow-up and management due to their propensity to enlarge and/or mimic malignancy. In the case of hepatic adenoma, malignant transformation and tumour haemorrhage/rupture are the key concerns. This paper will discuss the clinical course of these two entities, their typical imaging findings on a range of modalities and how this impacts decision-making at the clinical level. The utility of hepatobiliary-specific MRI contrast agents will be discussed with reference to their key role in differentiating FNH from hepatic adenoma, whilst highlighting limitations and potential interpretation pitfalls.
Indexed as
Identifiers
42541546What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.